TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Seasonal Affective Disorder~* Age 18 to 65~Exclusion Criteria:~* Psychotropic medication treatment~* History of light treatment for SAD~* History of mania or psychosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Inactivated negative ion generator (Type: EXPERIMENTAL): Equivalent exposure to inactivated Negative Ion Generator
- LED light treatment device (Type: EXPERIMENTAL): Light-emitting photodiode light treatment device, used for 30 min before 8 am

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the pancreas~  * Locally advanced or regional (encompassable within the same radiotherapy portals)~ * Adenosquamous cancers are allowed~* Unresectable disease~* Measurable and/or non-measurable disease as determined by computed tomography (CT) scan or magnetic resonance imaging (MRI), which must be performed within 4 weeks prior to randomization.~* Age\>=18~* ECOG Performance status of 0-1~* Life expectancy \>= 12 weeks~* Adequate bone marrow reserve,liver and renal function within 2 weeks of randomization:~  * Absolute granulocyte count at least 2,000/mm\^3~ * Platelet count at least 100,000/mm\^3~ * Bilirubin less than 3 mg/dL (unless secondary to biliary obstruction or cholangitis)~ * Serum glutamic-oxaloacetic (AST) less than 5 times upper limit of normal (ULN)~ * Albumin greater than 2.5 g/dL~ * Creatinine no greater than 1.5 times ULN~* Fertile patients must use effective contraception~* Willing and able to attend follow-up visits~* Concurrent enrollment on protocol ECOG-E1Y03 allowed~* More than 4 weeks since prior investigational agents~Exclusion Criteria:~* Candidate for surgical excision based on local extent of disease (e.g., T3, N1, M0)~* Stage M1 disease~* Small cell, mucinous cystadenocarcinoma, islet cell or papillary cystic histology~* Pregnant or nursing~* Active infection within within 4 weeks of randomization~* Malignancy within the past 5 years except nonmelanoma skin cancer, carcinoma in situ of the cervix, or organ-confined prostate cancer (Gleason score no greater than 7)~* History of active collagen vascular disease (i.e., systemic lupus erythematosus, rheumatoid arthritis, or scleroderma)~* Signs or symptoms of peptic or duodenal ulcer disease~* Concurrent serious systemic disorders that are incompatible with study participation~* Prior chemotherapy for pancreatic cancer~* Prior radiotherapy~* Concurrent intensity modulated radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemcitabine (Type: ACTIVE_COMPARATOR): None
- Gemcitabine + Radiation (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PMZ-2010 (Centhaquine) as a Resuscitative Agent for Hypovolemic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult males or females aged 18-70 years.~* Patients with Hypovolemic shock due to blood loss admitted to the emergency room or ICU with systolic blood pressure ≤ 90 mmHg at presentation and continue to receive standard shock treatment (endotracheal intubation; fluid resuscitation and vasopressors). Standard of care to be provided to the patients shall be the one used in the particular hospital setup.~* Body weight 45 kg - 85 kg.~* Female subject is either: (1) Not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) or, (2) If of childbearing potential, agrees to use any of the following effective separate forms of contraception throughout the study, up to and including the follow-up visits: Condoms, sponge, foams, jellies, diaphragm or intrauterine device, or A vasectomised partner OR abstinence.~Exclusion Criteria:~* Terminal illness~* Development of any other terminal illness not associated with Hypovolemic shock due to blood loss during the 28 day observation period~* Patient with severe brain injury or with a Glasgow Coma Scale (GCS) \< 8~* Type of injury is not known~* Inability to obtain intravenous access~* Known pregnancy~* Cardiopulmonary resuscitation (CPR) before randomization~* Presence of a do not resuscitate order~* Patient taking beta adrenergic antagonists~* Untreated tension pneumothorax~* Untreated cardiac tamponade~* Bilateral absent pupillary light reflex (both pupils fixed and dilated)~* Patient is participating in another interventional study~* Patients with systemic diseases which were already present before having trauma, such as: cancer, chronic renal failure, liver failure, decompensated heart failure or AIDS

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Normal Saline (Type: ACTIVE_COMPARATOR): Hypovolemic shock patients will be provided the standard of care. Following randomization 100 ml (equal volume to experimental arm) of normal saline will be administered intravenously over 1 hour.
- PMZ-2010 (centhaquine) (Type: EXPERIMENTAL): Hypovolemic shock patients will be provided the standard of care. Following randomization PMZ-2010 (0.01 mg/kg) will be administered intravenously over 1 hour in 100 mL of normal saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sedation by Dexmedetomidine and Propofol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Surgery under spinal anesthesia~* Intraoperative sedation~* American Society of Anesthesiology physical status 1 or 2~* Apnea/hypopnea index 5-14/h in Watch-PAT 200 analysis~Exclusion Criteria:~* Anatomical defects on upper respiratory tract~* Psychotic disorder~* Drug addition~* Alcohol addition~* body mass index ≥ 35 kg/m2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine (Type: EXPERIMENTAL): Intraoperative sedation is performed by using dexmedetomidine.
- Propofol (Type: EXPERIMENTAL): Intraoperative sedation is performed by using propofol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Shinabro in Hand Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age of 40 years or older~* Osteoarthritis according to ACR 1990 criteria~* Mean joint visual analog pain score (VAS) \> 30mm in the preceding 48 hours~* Patients who are will to participate~Exclusion Criteria:~* Any prior surgery of hand joints~* prior history of Shinbaro use~* Intra-articular injection of glucocorticosteroid or hyaluronic acid in the preceding 3 months~* Pregnancy or active breast feeding~* Prior hypersensitivity reaction to herbal medications~* AST or ALT elevation \> 3 of upper normal limit~* GRF (MDRD) \< 30 mg/min/1.73m2~* Nephrotic syndrome, other signficant kidney disease~* Patients who seem not to tolerate the study at investigator's discretion~* Patients who refuse to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 2 capsules, twice daily, for 12 weeks.
- Shinbaro (Type: ACTIVE_COMPARATOR): Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Sitting SBP ≥140 mm Hg and \< 160 mmHg on one antihypertensive agen or~* Sitting SBP ≥ 150 mm Hg and \< 180 mm Hg on no antihypertensive treatment.~Exclusion Criteria:~* Congestive heart failure (clinically defined).~* Serum creatinine levels greater than 170 µmol/l or estimated glomerular filtration rate (eGFR) \< 30 ml/min.~* History of coronary heart disease (i.e., chronic stable angina, myocardial infarction or acute coronary syndrome).~* History of a stroke or other cerebrovascular accident (i.e. transient ischaemic attack or reversible ischaemic neurological deficit).~* Known or suspected secondary hypertension.~* Any other concomitant illness, physical or mental impairment that could interfere with the effective conduct of the study.~* Pregnancy or those of child-bearing age who are not taking reliable contraception.~* Patients with a history of intolerance to any of the study medications for example angioedema or dry cough with angiotensin converting enzyme inhibitors.~* Patients on maximum dose of any of the study medications as monotherapy (i.e. amlodipine 10 mg/day or hydrochlorothiazide 25 mg/day or perindopril 8 mg/day)~* Gout.~* Serum potassium \< 3.5mmol/L at screening.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Perindopril plus Amlodipine at a dose of 4mg/5mg once daily for two months and 8mg/10mg once daily for the remaining four months.
- 2 (Type: ACTIVE_COMPARATOR): Perindopril Plus Hydrochlorothiazide at a dose of 4mg/12.5mg and 8mg/25mg once daily for the remaining four months.
- 3 (Type: ACTIVE_COMPARATOR): Amlodipine plus Hydrochlorothiazide 5mg/12.5mg for two months and 10mg/25mg for the remaining four months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Early Versus Late Enteral Iron in Infants Less Than 1301 Grams

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Inborn infant~* Birth weight of \<1301 g~* Admitted between June 1996 and June 1999~Exclusion Criteria:~* Major anomalies~* Hemolytic disease~* Twin-to-twin transfusion syndrome~* Missing parental consent

- Gender: ALL
- Minimum Age: 3 Days
- Maximum Age: 7 Days
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Female, 18 years or older~* Histologically confirmed invasive breast cancer~* Bone metastases~* ECOG Performance Status of 0 to 2~* Life expectancy of more than 3 months~* Subject must have adequate organ function:~  * Cr ≤ 3 mg/dL (265 µmol/L)，~ * CrCl (Cockcroft \& Gault) ≥ 30 mL/min，~ * Ca2+ \> 8.0 mg/dL (2.0 mmol/L) and ≤ 12 mg/dL (3.0 mmol/L)~* Negative serum pregnancy test for women with childbearing potential~* Good conditions for infusion and willing to undergo phlebotomy during the whole study~* Have ceased anti-tumor treatment including chemotherapy, endocrinotherapy and bio-targeted therapy for over 28 days~Exclusion Criteria:~* Pregnant or lactating females~* History of other malignancy. However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.~* Concurrent disease or condition that would make the subject inappropriate for study participation, or any serious medical disorder that would interfere with the subject's safety~* Active or uncontrolled infection~* Current active dental problems including infection of the teeth or jawbone (maxilla or mandible); dental or fixture trauma; or a current or prior diagnosis of osteonecrosis of the jaw (ONJ); or exposed bone in the mouth; or slow healing after dental procedures~* Recent (within 6 weeks of Randomization) or planned dental or jaw surgery (e.g. extraction, implants)~* Known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure~* Concomitant with liver, brain or symptomatic lung metastases (symptoms such as hemoptysis, severe cough and shortness of breath)~* Accepted radiotherapy for solitary bone disease within 30 days before study~* Previous treatment with other bisphosphonates or radionuclides within one month before study~* Known hypersensitivity to bisphosphonates~* History of treatment with calcitonin, gallium nitrate or mithracin within 14 days before study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- conventional Zometa (Type: ACTIVE_COMPARATOR): Zometa 4mg IV q4w, in combination with other antitumor agents one month after the initial dosing.
- weekly Zometa (Type: EXPERIMENTAL): Weekly Zometa in combination with other antitumor agents one month after the initial dosing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fasting LDL-C at screening \> 85 mg/dL~* Fasting triglycerides less than or equal to 400 mg/dL (4.5 mmol/L) Exclusion Criteria:~* New York Heart Association (NYHA) III or IV heart failure~* Uncontrolled cardiac arrhythmia~* Uncontrolled hypertension~* Type 1 diabetes or poorly controlled type 2 diabetes~* Uncontrolled hypothyroidism or hyperthyroidism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Evolocumab PFS (Type: EXPERIMENTAL): Participants received evolocumab 140 mg every 2 weeks for 4 weeks (Day 1, Week 2, and Week 4) subcutaneously using a prefilled syringe (PFS). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 2 and 4.
- Evolocumab AI/pen (Type: EXPERIMENTAL): Participants received evolocumab 140 mg every 2 weeks for 4 weeks (Day 1, Week 2, and Week 4) subcutaneously using a prefilled autoinjector/pen (AI/pen). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 2 and 4.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the 755nm Alexandrite for Unwanted Tattoos

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Is a healthy male or female between 18 and 85 years old.~2. Has unwanted non-cosmetic tattoo(s) and wishes to undergo laser treatments to remove them.~3. Is willing to consent to participate in the study.~4. Is willing to comply with all requirements of the study including being photographed, following post treatment care and attending all treatment and follow up visits.~Exclusion Criteria:~1. Is hypersensitive to light exposure.~2. Has active localized or systemic infection.~3. Is taking medication(s) for which sunlight is a contraindication.~4. Has a history of squamous cell carcinoma or melanoma.~5. Has a history of keloid scarring.~6. Has used oral isotretinoin (Accutane®) within 12 months of initial treatment or plans on using during the course of the study. Note: Skin must regain its normal degree of moisture prior to treatment.~7. Has a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications.~8. Is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period.~9. Is allergic to lidocaine, tetracaine or Xylocaine with epinephrine.~10. Has any other reason determined by the physician to be ineligible to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 755nm Alexandrite Laser Single Pass (Right Side). (Type: EXPERIMENTAL): 755nm Alexandrite Laser for Treatment of unwanted, non cosmetic tattoos. The right side will be treated once within the same visit.
- 755nm Alexandrite Laser Double Pass (Left Side) (Type: EXPERIMENTAL): 755nm Alexandrite Laser for Treatment of unwanted, non cosmetic tattoos. The left side of the tattoo will be treated twice within the same visit 20 minutes apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 Diabetes Mellitus of mor than 1year~* GFR less than 30 ml/min/1.73m2 or dialysis~* Age greater than 18years~* Entry blood glucose (fasting or random) greater than 180mg%~Exclusion Criteria:~* Type 1 Diabetes Mellitus~* New onset hyperglycemia~* Pregnant~* Solid organ transplant within 1 year~* Steroids prednisone greater than 7.5mg/day or equivalent~* Hospital LOS predicted less than 2 days~* Severe liver disease~* Known hypopituitarism or adrenal insufficiency~* Patients in the ICU~* Patients with hypoglycemic unawareness~* Outpatient insulin dose less than 0.6 units/kg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0.5 units/kg (Type: ACTIVE_COMPARATOR): Participants randomized to this arm will receive a standard-dose of 0.5 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
- 0.25 units/kg (Type: EXPERIMENTAL): Participants randomized to this arm will receive an experimental dose of 0.25 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bronx MBCT-Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ICHD-3 beta headache diagnosis of migraine,~* self-reported and diary-confirmed 4-20 headache days per month~* aged 18-65~* ability to read English~* capacity to consent.~Exclusion Criteria:~* no ICHD-3 beta headache diagnosis of migraine~* fewer than 4 or greater than 20 headache days per month~* under 18 or over 65~* inability to read English~* lacking the capacity to consent~* utilization of new preventative pain treatments within four weeks of the baseline assessment, or a plan to utilize new preventive pain medications during the duration of the study~* severe psychiatric illness that would interfere with participation in the treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MBCT for Migraine (Type: EXPERIMENTAL): In this arm, participants will receive 8 weeks of the manualized treatment Mindfulness Based Cognitive Therapy (MBCT; Day \& Thorn). Participants will attend weekly 75-90 minute individual sessions for eight weeks. At each weekly session one of eight broad topics are addressed and discussed (Automatic-Pilot, Dealing with Barriers, Mindfulness of Breath, Staying Present, Allowing/Letting Be, Cognitive Restructuring, Self Care, Application to Headache Pain). Homework is assigned each week, and participants are expected to develop a daily formal mindfulness practice (body scan meditation, seated meditation, breathing meditation, etc). Participants are provided with a course manual, reading materials, and audio recordings to facilitate meditation practice.
- Wait List/Treatment as Usual (Type: NO_INTERVENTION): Patients will continue with standard care. Patients will be offered MBCT after the primary endpoint.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete